Quick Summary:
- Regeneron Pharmaceuticals and Sanofi receive FDA approval for Dupixent's expanded use.
- Analysts predict a significant upside for Regeneron's stock price.
- GuruFocus estimates suggest a potential 69.1% appreciation in the stock's value.
Regeneron Pharmaceuticals (REGN, Financial) alongside Sanofi has successfully garnered FDA approval to broaden the application of their medication, Dupixent, now treating the rare skin condition bullous pemphigoid, with a higher prevalence in the elderly population. This approval was granted following compelling outcomes from the ADEPT study, underlining the drug's effectiveness in symptom management.
Wall Street Analysts Forecast
In the realm of Wall Street projections, 24 analysts have posited that the average one-year price target for Regeneron Pharmaceuticals Inc (REGN, Financial) stands at $735.55, with estimates spanning from a high of $1,013.00 to a low of $504.00. This average target price suggests a substantial upside of 43.22% from the current trading price of $513.58. For a comprehensive overview of these estimates, please explore the Regeneron Pharmaceuticals Inc (REGN) Forecast page.
Brokerage Recommendations
The current consensus from 28 brokerage firms rates Regeneron Pharmaceuticals Inc's (REGN, Financial) stock with an average recommendation of 2.0, classifying it as "Outperform." The rating scale utilized ranges from 1 to 5, where 1 indicates a Strong Buy, and 5 signifies Sell, reflecting positive sentiment towards the stock.
GF Value Estimation
According to GuruFocus metrics, the projected GF Value for Regeneron Pharmaceuticals Inc (REGN, Financial) a year from now is $868.46. This estimation points to a notable upside of 69.1% from the current price of $513.58. The GF Value represents GuruFocus' assessment of the stock's fair trading value, derived from historical trading multiples, historical and projected business growth. Additional details are accessible on the Regeneron Pharmaceuticals Inc (REGN) Summary page.
